Share

Tesaro: Next big thing in biotech?

Lonnie Moulder, Tesaro CEO, discusses the drug Rolapitant, which controls the effects of chemotherapy. Moulder says it's not about market share but about accessing patients who should receive the drug.
02:38
Mon, Jan 13 20145:45 PM EST